Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sitagliptin on Lobeglitazone PK in Healthy Males
NCT02824874Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve over dosing interval (AUCtau) at Day 7 and Maximum Steady State Concentration (Css,max) at Day 7. Started Apr 2016; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02824874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824874.